Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $55.00

Amylyx Pharmaceuticals (NASDAQ:AMLX) had its price objective boosted by investment analysts at HC Wainwright from $34.00 to $55.00 in a research report issued on Tuesday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 41.42% from the stock’s current price. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ FY2028 earnings at ($0.97) EPS, FY2029 earnings at $3.22 EPS and FY2030 earnings at $6.40 EPS.

Other equities research analysts have also issued research reports about the stock. Citigroup increased their price objective on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Guggenheim upped their target price on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Mizuho lifted their price target on Amylyx Pharmaceuticals from $24.00 to $30.00 and gave the stock an “outperform” rating in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $36.25.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX stock traded up $0.29 during mid-day trading on Tuesday, hitting $38.89. The company’s stock had a trading volume of 3,483,750 shares, compared to its average volume of 1,607,203. The company has a market cap of $4.33 billion, a PE ratio of -27.20 and a beta of -0.21. The company’s fifty day simple moving average is $19.38 and its 200-day simple moving average is $16.35. Amylyx Pharmaceuticals has a 52 week low of $7.96 and a 52 week high of $39.93.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). On average, equities analysts anticipate that Amylyx Pharmaceuticals will post -1.45 earnings per share for the current year.

Insider Activity at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the transaction, the insider directly owned 194,090 shares in the company, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.90% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. purchased a new position in Amylyx Pharmaceuticals during the 4th quarter valued at about $25,000. KBC Group NV bought a new stake in shares of Amylyx Pharmaceuticals in the 1st quarter worth approximately $26,000. California State Teachers Retirement System bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $28,000. State of Wyoming purchased a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $40,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Amylyx Pharmaceuticals by 954.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock valued at $47,000 after acquiring an additional 3,493 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Key Headlines Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Avexitide achieved the primary endpoint in the Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, reducing hypoglycemic events by 55%. The result strengthens the case for an FDA filing by the end of 2026 and improves the drug’s potential commercial value. AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
• Positive Sentiment: Analysts raised their outlook for Amylyx. HC Wainwright maintained a Buy rating and a $55 price target while increasing its EPS forecasts to $3.22 for 2029 and $6.40 for 2030, reflecting expectations for successful commercialization and substantially higher future revenue. HC Wainwright Raises Amylyx Price Target
• Positive Sentiment: Guggenheim raised its price target to $55 from $40 with a Buy rating, while Robert W. Baird increased its target to $52 from $28 and assigned an Outperform rating. Wolfe Research also upgraded the shares to Strong Buy, adding to the positive analyst momentum.
• Neutral Sentiment: The clinical success has pushed AMLX toward regulatory and commercial execution milestones. Investors will now focus on additional LUCIDITY data, the FDA filing, approval prospects and Amylyx’s ability to establish avexitide commercially.
• Negative Sentiment: Amylyx priced an upsized public offering of 14.09 million shares at $35.50 per share, expected to raise approximately $500 million before expenses. Underwriters may purchase another 2.11 million shares, creating potential dilution and adding supply near the offering price. Amylyx Prices Upsized $500 Million Offering

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on therapies intended to protect nerve cells and address the underlying biology of conditions such as amyotrophic lateral sclerosis (ALS) and other serious neurological disorders.

Amylyx’s lead product, AMX0035, was marketed in the United States as Relyvrio and in Canada as Albrioza for the treatment of ALS. Following results from a confirmatory clinical trial that did not meet its objectives, the company announced the voluntary withdrawal of the product from the market in 2024.